Drug Name Pretomanid
CAS: 187235-37-6
Original Research Company: Novartis
Co-development: TB Alliance, Viatris Inc
Indications: combination of bedaquiline and linezolid (BPaL regimen) for the treatment of extensively drug-resistant (XDR) in the lungs of adults, for the treatment of multidrug-resistant tuberculosis in which there is intolerance or non-response.
On 14 August 2019, Pretomanid was approved by the US Food and Drug Administration (FDA) for the treatment of some of the most drug-resistant forms of tuberculosis (TB).
On 26 March 2020,Pretomanid has received conditional marketing authorisation from the European Commission (EC) for the treatment of highly drug-resistant forms of tuberculosis (TB).
TB is the second most infectious killer globally after 2019 coronavirus disease (above HIV and AIDS).In 2022, an estimated 10.6 million people worldwide will have TB, including 5.8 million men, 3.5 million women, and 1.3 million children.A total of 1.3 million people will die of TB in 2022 (including 167,000 people living with HIV). TB is present in all countries and age groups. TB is curable and preventable. Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis and a health security threat.In 2022, only about two-fifths of people with drug-resistant TB will have access to treatment. Since 2000, global efforts to combat TB have saved an estimated 75 million lives. US$13 billion is needed annually for TB prevention, diagnosis, treatment and care.
Currently, the main TB treatment drugs are:
First-line drugs
Rifampin, Isoniazid, Pyrazinamide, Ethambutol
Second-line drugs
Kanamycin (no longer used in the United States), Streptomycin, Capreomycin, Amikacin, Levofloxacin Moxifloxacin, Gatifloxacin
Multidrug-resistant tuberculosis (MDR-TB)
Bedaquiline, Delamanid, Linezolid, Pretomanid.
